2019 Cell & Gene Therapies State of the Industry Briefing will be held in San Francisco on January 7 with webcasted company presentations to begin at 11 am; not all company presentations may be webcasted.
Monday, January 7, 2019
Piper Jaffray views price paid for Loxo by Eli Lilly as fair
Piper Jaffray analyst Tyler Van Buren views the price of $235 per share paid by Eli Lilly (LLY) for Loxo Oncology (LOXO) as fair. The analyst says the price is near the $250-plus he previously thought was achievable in an acquisition scenario for Loxo. Other names in the precision medicine/oncology space that could be up today as a result of the buyout are Agios Pharmaceuticals (AGIO), ArQule (ARQL), Array BioPharma (ARRY), Blueprint Medicines (BPMC), Kura Oncology (KURA), Mirati Therapeutics (MRTX) and others, Van Buren tells investors in a research note. He raised his price target for Loxo Oncology to $235 from $200 and keeps an Overweight rating on the shares.
Allscripts sees non-GAAP 3-year revenue CAGR 5.5%-9%
Sees non-GAAP revenue CAGR for 2019-2021 of 5.5%-9%. Comments taken from slides that will be presented at the 37th Annual J.P. Morgan Healthcare Conference.
https://thefly.com/landingPageNews.php?id=2844701
CytoSorbents sees FY18 revenue at least $22.3M, consensus $22.71M
The company expects to announce record results including: Full year 2018 total revenue of at least $22.3M, with additional 2018 grant revenue expected upon finalization of invoicing; Full-year product sales in 2018 of approximately $20.2M, an increase of approximately 51% compared to $13.4M in 2017, and record Q4 2018 product sales of approximately $5.4M; 2018 blended gross product margins in excess of 72%, mixing higher margin direct sales and lower margin distributor and partner sales; More than 56,000 CytoSorb cumulative treatments delivered, up from 35,000 treatments a year ago; End-of-year cash position of approximately $22.3M (12/31/18).
https://thefly.com/landingPageNews.php?id=2844703
Eli Lilly says ‘very much’ wants to continue Loxo’s partnership with Bayer
https://thefly.com/landingPageNews.php?id=2844705
STAAR Surgical sees FY18 revenue about $124M, consensus $123.27M
“Global demand for our ICL product lines continued to expand during the fourth quarter, and all signs currently point to this momentum continuing into 2019,” said Caren Mason, President and CEO. “China led the way with ICL unit growth of approximately 99% in the fourth quarter, sequentially consistent with the growth we reported for the third quarter of 2018. As we planned, STAAR Surgical’s business in the U.S. also returned to growth. We began the staged rollout of the Toric ICL in the U.S. to certified surgeons in late October leading to approximately 16% growth for the ICL in the U.S., compared to the prior year period, in the world’s second largest refractive surgery market.”
https://thefly.com/landingPageNews.php?id=2844711
Subscribe to:
Posts (Atom)